Here we show that simultaneously considering activin and TGF-β serum ligand levels is superior to assessing either ligand alone in identifying patients with advanced CRC and assessment of serum ligand levels is feasible as a clinical assay to guide treatment options. The gene discussed is TGFB1; the disease is colorectal carcinoma.